by admin_prosemble | 1st March 2025 | News
A warm welcome to our new team members: Sadie Hallett has joined us as a Senior Scientist, where she will be supporting our in vivo mouse trials. Ludovico Pipito is leading the advancement of our AI model for drug cocktails. Tadas Vilkas, on secondment from Moterra,...
by admin_prosemble | 28th February 2025 | News, Uncategorized
Latest paper from the lab: the cryo-EM structure of BeeRA family of bacterial actin homologues forms a 3-stranded tubular structure…Latest paper from the lab: the cryo-EM structure of BeeRA family of bacterial actin homologues forms a 3-stranded tubular...
by admin_prosemble | 24th January 2025 | News, Research
Prosemble proudly announces that its initial angel investor funding round has been oversubscribed. This strong support underscores confidence in our mission to transform precision therapies.
by admin_prosemble | 13th January 2025 | News, Research
Prosemble begins Immunogenicity/Tox Studies, including Toxicity Study in NCG immunodeficient mice, in collaboration with TransCure BioServices. Exciting progress ahead! transcurebioservices.com
by admin_prosemble | 11th December 2024 | News, Research
The cytoskeleton is essential for cell organisation and movement, with actin filaments in eukaryotes and actin-like proteins in bacteria playing key roles. This study identifies a novel bacterial actin family in the Verrucomicrobiota phylum, forming unique...
by admin_prosemble | 2nd December 2024 | News
Prosemble is pleased to announce the successful completion of its angel investor funding round. This milestone marks a significant step forward in advancing our mission to revolutionise precision therapies.
